Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Crohn Disease

  • Gerard Dijkstra
  • Maikel P. Peppelenbosch
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1379-2



Crohn’s disease (also: regional enteritis) and ulcerative colitis area chronic, inflammatory conditions of the gastrointestinal tract. Although the inflammation of the mucosa is usually episodic in nature, these Inflammatory bowel diseases (IBD) are associated with an increased risk of developing colorectal cancer. Inflammatory bowel disease well-managed patients suffering from IBD have an approximately two times higher chance for contracting CRC as the population at large.


Inflammatory bowel disease (IBD) patients, which include the two related conditions of Crohn’s disease and ulcerative colitis, have an increased risk of developing colorectal cancer (CRC) (Itzkowitz and Yio 2004). For patients with Crohn’s disease [CD], the excess risk for contracting CRC has been estimated at 1.9, whereas the risk for small bowel cancer is 27.1...


Inflammatory Bowel Disease Ulcerative Colitis Familial Adenomatous Polyposis Primary Sclerosing Cholangitis Sclerosing Cholangitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Baan B, Dihal AA, Hoff E, Bos CL, Voorneveld PW, Koelink PJ, Wildenberg ME, Muncan V, Heijmans J, Verspaget HW, Richel DJ, Hardwick JC, Hommes DW, Peppelenbosch MP, van den Brink GR (2012) 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut 61(12):1708–1715CrossRefPubMedGoogle Scholar
  2. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ (2006) Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27:2371–2382CrossRefPubMedGoogle Scholar
  3. Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, O’Brien PE (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45:1578–1584CrossRefPubMedGoogle Scholar
  4. Chu EC, Chai J, Ahluwalia A, Tarnawski AS (2007) Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ther 25:1443–1449CrossRefPubMedGoogle Scholar
  5. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J (2000) Colorectal cancer prevention in ulcerative colitis: a case–control study. Aliment Pharmacol Ther 14(2):145–153CrossRefPubMedGoogle Scholar
  6. Gong W, Lv N, Wang B, Chen Y, Huang Y, Pan W, Jiang B (2012) Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci 57(2):503–507CrossRefPubMedGoogle Scholar
  7. Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17CrossRefPubMedGoogle Scholar
  8. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI (2005) Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729CrossRefPubMedGoogle Scholar
  9. Lindberg BU, Broomé U, Persson B (2001) Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 44(1):77–85CrossRefPubMedGoogle Scholar
  10. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C (2007) 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 132:221–235CrossRefPubMedGoogle Scholar
  11. Monteleone G, Franchi L, Fina D, Caruso R, Vavassori P, Monteleone I et al (2006) Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 13:202–221CrossRefPubMedGoogle Scholar
  12. Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2):1–5CrossRefPubMedGoogle Scholar
  13. Nguyen GC, Gulamhusein A, Bernstein CN (2012) 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 107(9):1298–1304CrossRefPubMedGoogle Scholar
  14. Pinczowski D1, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case–control study. Gastroenterology 107(1):117–20Google Scholar
  15. Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D et al (2000) Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32:245–254CrossRefPubMedGoogle Scholar
  16. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR (2013) Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case–control study. Clin Gastroenterol Hepatol 11(12):1601–8.e1–1601–8.e4CrossRefGoogle Scholar
  17. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB (2006) Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4(11):1346–1350CrossRefPubMedGoogle Scholar
  18. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126(2):451–459CrossRefPubMedGoogle Scholar
  19. Schroeder KW (2002) Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl 236:42–47CrossRefPubMedGoogle Scholar
  20. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O et al (2008) PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29:1407–1414CrossRefPubMedGoogle Scholar
  21. Stolfi C, Fina D, Caruso R, Caprioli F, Fantini MC, Rizzo A et al (2008) Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 29:1258–1266CrossRefPubMedGoogle Scholar
  22. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology 130(7):1941–1949CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
  2. 2.Erasmus Medical Center2University Medical Center RotterdamRotterdamThe Netherlands